Travere Therapeutics, Inc. TVTX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s EPS (diluted)?
- Travere Therapeutics, Inc. (TVTX) reported EPS (diluted) of -$0.40 in Q1 2026.
- How has Travere Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Travere Therapeutics, Inc.'s EPS (diluted) increased by 14.9% year-over-year, from -$0.47 to -$0.40.
- What is the long-term trend for Travere Therapeutics, Inc.'s EPS (diluted)?
- Over 3 years (2021 to 2024), Travere Therapeutics, Inc.'s EPS (diluted) has grown at a 10.4% compound annual growth rate (CAGR), from -$3.03 to -$4.08.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.